The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited
Abstract
OBJECTIVE— The Diabetes Control and Complications Trial (Diabetes 44:968–983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS— We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS— Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS— A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006) · Diabetes Care · doi:10.2337/dc06-0293 · Cited by 377
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Self-citation
Cited by
Items 501–555 of 555
Hinz, H. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-hzbm-5q36
Arroyo‐Fernández, I., Sánchez-Rojas, J. A., Téllez‐Velázquez, A., Juárez-Martínez, F., Cruz‐Barbosa, R., Guzmán‐Ramírez, E., & Balderas-Martínez, Y. I. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2111.13781
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Current literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.907
Quinn, L. M., Thayakaran, R., Thomas, G. N., Nirantharakumar, K., & Narendran, P. (2022) · Diabetes Care · doi:10.2337/dc21-2372
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00004-x · Cited by 1
Reynaud, R., Bendelac, N., & Coutant, R. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00009-4
Sämann, A., & Wolf, G. (2013) · Humanmedizin kompakt · doi:10.1007/s40355-012-0006-x
Dreyer, M. (2020) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_3-2
Almokayyad, R. M., & Cuddihy, R. M. (2011) · Wiley eBooks · doi:10.1002/9781444340280.ch5
Dreyer, M. (2015) · Springer eBooks · doi:10.1007/978-3-642-54676-1_3-1
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., Ruggenenti, P. L., & Remuzzi, G. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_23
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00009-9 · Cited by 1
Forga, L., López‐Andrés, N., Tamayo, I., Fernández‐Celis, A., Mouriz, M. G., & Goñi, M. J. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.02.006
Moreno-Fernández, J., García-Seco, J. A., Virlaboa-Cebrian, R., Seco, A. M., Muñoz‐Rodríguez, J. R., & Romero, F. J. G. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.12.011
Research Progress of the Predictive Value of Color Dopplor Ultrasonography in Diabetic Retinopathy
许, 昕. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281006
Diabetische Retinopathie und Makulopathie
Hammes, H., Lemmen, K. D., & Bertram, B. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1916-2141
Akbaş, E. M., & Akbaş, N. (2023) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1226971 · Cited by 1
Look in or book in: The case for type 2 diabetes remission to prevent diabetic retinopathy
Cripps, J., & Cucuzzella, M. T. (2023) · Journal of Metabolic Health · doi:10.4102/jir.v6i1.79
“23,24,25,26,27,28 Damage to neural retinal, supportive cells and endothelial microvasculature results in a breakdown of the blood-retinal barrier, a proinflammatory milieu, production of vascular endothelial growth factor (VEGF) and retinal dysfunction with apoptosis, haemorrhage, macular edema and…”
Sharma, N., Mushriff, S., & Nigoskar, S. (2023) · International Journal of Research and Review · doi:10.52403/ijrr.20230757
Volkskrankheit diabetische Retinopathie
Spital, G., & Faatz, H. (2023) · Diabetes aktuell · doi:10.1055/a-2184-5141
Al-Rawi, H. A. (2022) · Journal of Sulaimani Medical College · doi:10.17656/jsmc.10361
Abraham, D., Sisay, S., Huri, H. Z., Shin, S. M., Kumar, L. N., Kebede, T., Tegene, B., Ephrem, E., & Workineh, S. (2023) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410176
Iqbal, A., Chow, E., Jones, T. W., & Heller, S. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch40
Role of newer anti-diabetes drugs in prediabetes: A systematic review
Singh, A. K., & Singh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00037-2
Ghazipura, A. F., Achakzai, N. U., Gaintry, Rehman, A. U., & Cheema, A. (2024) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v40i2.1718
Additional file 2 of Plasma metabolomic profiling of proliferative diabetic retinopathy
Zhu, X.-R., Yang, F., Lu, J., Zhang, H., Sun, R., Zhou, J., & Yang, J. (2019) · Figshare · doi:10.6084/m9.figshare.8196959
Additional file 1 of Plasma metabolomic profiling of proliferative diabetic retinopathy
Zhu, X.-R., Yang, F., Lü, J., Zhang, H., Sun, R., Zhou, J., & Yang, J. (2019) · Figshare · doi:10.6084/m9.figshare.8196953
Magar, B. P., Thapa, A., Acharya, S., Ghimire, N., Pandey, S. K., Rokaya, R. K., & Lamichhane, S. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6424
“In the USA percentage (%), HbA1 c (recommended by NGSP) unit is accepted, however IFCC accepts both units, but IFCC recommends using mmol HbA1c/mol 38,39 .”
Methodde Assis, S. I. S. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2024.tde-03072024-122500
Data analytic models of patients dependent on insulin treatment
Adetuyi, T. G., Adetuyi, B. O., Okunlola, F. O., Oni, P. G., Olajide, P. A., Omolehin, P. T., Adetunji, C. O., Adetunji, M. C., & Oyewole, O. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95686-4.00017-4
López-Letayf, S., Vivanco-Rojas, Ó., Londoño-Angarita, V., Magaña‐Guerrero, F. S., Buentello‐Volante, B., & Garfias, Y. (2024) · Life · doi:10.3390/life14080976
“This is also because nerve damage is one of the main complications caused by diabetes [6,34–36].”
BackgroundDiabetische Retinopathie und Makulopathie
Hammes, H., Lemmen, K. D., & Bertram, B. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2376-9729
Liang, F., Tao, S., Zhang, Y., Liu, S., Huang, W., He, C., Fan, S., & Liu, X. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.03.034
Tan, J., Lim, G. H., Tan, H. Y., Sng, G. G. R., Thumboo, J., & Mong, B. Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5236698
HbA1C and Fructosamine levels during InfancyPreprint
Aguirre, R. S., Al-Raddadi, A., DiMeglio, L. A., & Eugster, E. A. (2025) · medRxiv · doi:10.1101/2025.05.07.25327198
Zhu, X., Lin, C., Li, Z., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70052
“Several previous studies indicated that intensive glycaemic control conferred limited extra cardiovascular benefit compared with standard care [20, 39, 40], and the inclusion of those studies might bring heterogeneity to the analyses and result in a negative result.”
Kim, A. Y., Kim, J. Y., Kim, S. G., Lee, G. W., & Lee, S. H. (2025) · Journal of Retina · doi:10.21561/jor.2025.10.1.38
Sakai, M., Kato, T., Ishihara, T., Takao, K., Hirose, T., Kubota, S., Kubota‐Okamoto, S., Imaizumi, T., Takahashi, Y., Mizuno, M., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590407 · Cited by 1
Fitzgerald, A. A., Das, R., Moezzi, C., Salazar, S. R., Mankad, R. N., Qualls, C., Cabrera, A. P., Kathuria, A., Monickaraj, F., Tzamaloukas, A. H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1638415
Chen, Y.-K., Lai, C., Wang, N., Wu, W., Lin, C.-H., Lee, C.-P., Chou, Y.-H., & Yang, Y.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-18806-0 · Cited by 3
“Considering that HbA1C and diabetes duration together accounted for only approximately 11% of the risk of DR development, our study underscored the necessity of incorporating additional independent factors like DKA into DR screening protocols 34 .”
Schuppisser, C., Ferri, F., Reusch, C. E., Glaus, T. M., & Zini, E. (2025) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x251376606
Weir, N. M. (2012) · Journal of Bioresource Management
Xing, Y., Wu, M., Liu, H., Li, P., Pang, G., Zhao, H., & Wen, T. (2024) · Figshare · doi:10.6084/m9.figshare.25329765
Diabetische Retinopathie und Makulopathie
Kopf, S., Helbig, H., Hammes, H., Lemmen, K. D., & Bertram, B. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8536
Diabetische Retinopathie und Makulopathie
Kopf, S., Helbig, H., Hammes, H., Lemmen, K. D., & Bertram, B. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01428-z
Cao, X., Li, X., Yu, H., Liu, Z., Zhou, F. L., Chen, Z., Shao, W., Zhao, Y., Yang, X., & Li, P. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113166
Rezki, A. (2019) · theses.fr (ABES) · doi:10.70675/392902d9z7810z4025zb9afz3081c32bac5d
Xu, X., Wang, D., Alam, U., Qiu, S., Ding, Y., Sun, Z., & Garrib, A. V. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103414
Nathan, D. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.03.008
Self-citationShang, F., Dholakia, K. Y., & Schallek, J. B. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348363
Fedotkina, O., Begum, M. C., Trịnh, X. T., Özgümüş, T., Åkerlund, M., Nilsson, P., Spíndola, L., & Lyssenko, V. (2026) · Acta Ophthalmologica · doi:10.1111/aos.70187
Gardner, T. W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00020-2
Chen, Y., Zhang, B., Liu, Y., Wang, H., Tong, L., Xi, G., Peng, W., & Pu, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1889928
“Complications (EDIC) Research Group calculated that HbA1c accounted for only up to 11% of the overall variation in the risk of diabetic complications and concluded that most of the remaining variation was associated with factors not captured by glycaemia (37).”
Clinical and genetic determinants of diabetic retinopathy
Liu, Y. (2014) · Discovery Research Portal (University of Dundee)
Metadata
- Authors
- Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group
- Affiliations
- George Washington University (US)
- Case Western Reserve University (US)
- Harvard University (US)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-04-01
- Volume
- 57
- Issue
- 4
- Pages
- 995-1001
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1992103610
- Cited by
- 555
- References
- 13
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 31 · 2023: 31 · 2022: 34 · 2021: 28 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 31 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 36 · 2012: 25
- FWCI
- 22.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH Clinical Center
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- glycemic exposure, glycemic variability, postprandial hyperglycemia, microvascular complications, diabetic retinopathy progression, HbA1c, tight glycemic control, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Insulin, Male, Reproducibility of Results, Models, Statistical, Cohort Studies, Biomarkers, Disease Progression, Patient Selection, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.